Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026 Based on its unique mode of binding JAK2, AJ1-11095 has the potential to deliver deeper and more...
Hence then, the article about lilly to acquire ajax therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera )
Also on site :
- Marshals Episode 9 Ends With Chilling Warning From Kayce's Nemesis: 'Like The Duttons, My Legacy Is Growing'
- ‘The Night Manager’ Team Discusses How One-Off Limited Series Became Trilogy, Vows That Season 3 “Won’t Take As Long As The Last One” – Contenders TV
- Oil prices rise higher amid stalled US-Iran peace talks